Palvella Therapeutics
PVLA
105 hedge funds and large institutions have $199M invested in Palvella Therapeutics in 2018 Q3 according to their latest regulatory filings, with 12 funds opening new positions, 38 increasing their positions, 29 reducing their positions, and 22 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
31% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 29
11% more capital invested
Capital invested by funds: $179M → $199M (+$20.4M)
0.01% more ownership
Funds ownership: 0.82% → 0.82% (+0.01%)
9% less funds holding
Funds holding: 115 → 105 (-10)
45% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 22
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $363K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
+$3.45M |
| 2 |
Millennium Management
New York
|
+$3.38M |
| 3 |
PM
Prosight Management
Dallas,
Texas
|
+$1.64M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$1.38M |
| 5 |
PAWC
P.A.W. Capital
Greenwich,
Connecticut
|
+$1.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$3.72M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$2.33M |
| 3 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$1.26M |
| 4 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$904K |
| 5 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$857K |
PVLA Hedge Fund Activity: Q3 2018 in Review
105 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q3 2018, worth a combined $199M — up 11% from $179M a quarter earlier.
Sellers outnumbered buyers: 22 funds closed out of PVLA and 12 opened new positions — a net loss of 10 holders — while 29 trimmed existing stakes and 38 added.
The largest buyer was Nantahala Capital Management, opening a new position worth an estimated $3.45M. The largest seller was OrbiMed, cutting an estimated $3.72M.
- 105 institutional investors held Palvella Therapeutics (PVLA) as of Q3 2018, down from 115 in Q2 2018.
- Funds reported $199M of Palvella Therapeutics stock for Q3 2018, up 11% quarter-over-quarter.
- 12 funds opened new Palvella Therapeutics positions in Q3 2018 and 22 closed out, a net change of -10 holders.
- The largest Palvella Therapeutics buyer in Q3 2018 was Nantahala Capital Management, an estimated $3.45M added.
- The largest Palvella Therapeutics seller in Q3 2018 was OrbiMed, an estimated $3.72M sold.
Based on aggregated 13F filings for Q3 2018.